Invasive aspergillosis: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{under construction}}{{englishcheck}}{{formatcheck}}{{editorcheck}} | {{under construction}}{{englishcheck}}{{formatcheck}}{{editorcheck}} | ||
<!---------------------------------------------------------------------------------------------------------------- | [[File:Aspergillosis.jpg|thumb|316x316px|Aspergillosis]]<!---------------------------------------------------------------------------------------------------------------- | ||
* VLOŽENÝ ČLÁNEK | * VLOŽENÝ ČLÁNEK | ||
* Pozor – tento článek je využíván dalšími články, do kterých je vložen. Buďte prosím opatrní při jeho editaci: | * Pozor – tento článek je využíván dalšími články, do kterých je vložen. Buďte prosím opatrní při jeho editaci: | ||
| Line 17: | Line 17: | ||
== Epidemiology == | == Epidemiology == | ||
Aspergils are '''ubiquitous''', occurring in the air, soil, dust, building materials, some foods, and water. The main route of entry for aspergillus is the '''respiratory tract.''' After inhalation, '''conidiospores''' mature in the lungs and can also penetrate other tissues through blood vessels if they are not controlled by the body's defense mechanisms.However, most people are naturally immune to the development of the disease because their alveolar '''[macrophages]]''' have the ability to absorb and destroy conidia. However,in patients treated with '''[kortikosteroids]]''' in immunodeficient patients (patients with leukemia, AIDS, COPD, patients after chemotherapy or transplantation, etc.), this ability is reduced. | Aspergils are '''ubiquitous''', occurring in the air, soil, dust, building materials, some foods, and water. The main route of entry for aspergillus is the '''respiratory tract.''' After inhalation, '''conidiospores''' mature in the lungs and can also penetrate other tissues through blood vessels if they are not controlled by the body's defense mechanisms.However, most people are naturally immune to the development of the disease because their alveolar '''[macrophages]]''' have the ability to absorb and destroy conidia. However,in patients treated with '''[kortikosteroids]]''' in immunodeficient patients (patients with leukemia, AIDS, COPD, patients after chemotherapy or transplantation, etc.), this ability is reduced. | ||
[[File:Cerebral aspergillosis in an immunocompromised child, HE.jpg|thumb|284x284px|Cerebral aspergillosis in an immunocompromised child]] | |||
== Risk factors == | == Risk factors == | ||
| Line 33: | Line 34: | ||
== Treatment == | == Treatment == | ||
Due to the possible progression of the disease, it is recommended to start treatment when IPA is suspected, before the diagnosis is confirmed by laboratory tests. Commonly used drugs are '''liposomal amphotericin B, voriconazole''' and echinocandin derivatives such as '''caspofungin''' or '''micafungin'''.<noinclude> | Due to the possible progression of the disease, it is recommended to start treatment when IPA is suspected, before the diagnosis is confirmed by laboratory tests. Commonly used drugs are '''liposomal amphotericin B, voriconazole''' and echinocandin derivatives such as '''caspofungin''' or '''micafungin'''.<noinclude> | ||
== References == | == References == | ||
=== Related Articles === | === Related Articles === | ||
Revision as of 22:46, 30 November 2021
|
This article was marked by its author as Under construction, but the last edit is older than 30 days. If you want to edit this page, please try to contact its author first (you fill find him in the history). Watch the discussion as well. If the author will not continue in work, remove the template Last update: Tuesday, 30 Nov 2021 at 10.46 pm. |
It is an infectious disease with high morbidity and mortality for immunocompromised patients caused by fungi of the genus Aspergillus, most often A. fumigatus.
Epidemiology
Aspergils are ubiquitous, occurring in the air, soil, dust, building materials, some foods, and water. The main route of entry for aspergillus is the respiratory tract. After inhalation, conidiospores mature in the lungs and can also penetrate other tissues through blood vessels if they are not controlled by the body's defense mechanisms.However, most people are naturally immune to the development of the disease because their alveolar [macrophages]] have the ability to absorb and destroy conidia. However,in patients treated with [kortikosteroids]] in immunodeficient patients (patients with leukemia, AIDS, COPD, patients after chemotherapy or transplantation, etc.), this ability is reduced.
Risk factors
The main risk factors for the development of IPA are neutropenia, solid organ transplantation (especially lung),hematopoietic stem cell transplantation (HSCT), chronic obstructive pulmonary disease (COPD), systemic corticosteroid therapy and haematological malignancies.
Other risk factors such as hepatic and renalfailure ,HIV, diabetes mellitus, malnutrition, autoimmune diseases or extensive burns.
In most cases, aspergils are trapped in the lower respiratory tract by inhalation of infectious spores. Less often, IPA can start from other sites, namely the paranasal sinuses, gastrointestinal tract and skin. The infection can spread through the bloodstream to other organs such as the brain, kidneys, liver, heart, pleura, etc.
Symptoms
The symptoms are non-specific and resemble bronchopneumonia: fever, cough, sputum formation, dyspnoea, chest pain of pleural origin due to vascular invasion leading to thrombosis and small pulmonary infarction, hemoptysis.
Diagnostika
The gold standard in the diagnosis of IPA is histopathological examination - samples of lung tissue obtained by thoracoscopy or open lung biopsy for the presence of septated, branched hyphae and positive cultures. Other options are sputum examination, BAL fluid, chest CT examination (presence of nodules and halo sign - zone of weakness around the lung nodules caused by hemorrhage and typical for neutropenic patients), ELISA test for detection of aspergillus antigens in body fluids (galactomannan - polysaccharide released from aspergillus after growth time) and PCR.
Treatment
Due to the possible progression of the disease, it is recommended to start treatment when IPA is suspected, before the diagnosis is confirmed by laboratory tests. Commonly used drugs are liposomal amphotericin B, voriconazole and echinocandin derivatives such as caspofungin or micafungin.
References
Related Articles
- Aspergillosis
- Allergic bronchopneumatic aspergillosis (ABPA)
- CNPA
- Aspergilom
- Aspergills infection
- Invasive fungal infections
External Links
Used Literature
- Incomplete citation of article. KOUSHA, M – TADI, R – SOUBANI, A.O. Pulmonary aspergillosis: a clinical review. 2011, no. 121, p. 156-162, Available from <www.ersjournals.com>. ISSN 1600-0617. DOI: 10.1183/09059180.00001011.
- WILLEY, Joanne M – SHERWOOD, Linda M – WOOLVERTON, Christopher J. Prescott,Harley, and Klein’s Microbiology. 7. edition. McGraw-Hill Hogher Education, 2008. ISBN 978-0-07-299291-5.
- EDITOR, Moselio – SCHAECHTER, Moselio Schaechter; consulting – LEDERBERG, Joshua. The desk encyclopedia of microbiology. 1. edition. Elsevier, 2004. ISBN 0-12-621361-5.
